Elevance Health (Elevance Health (ELV)) reported second-quarter results on Wednesday that beat Wall Street expectations. Adjusted earnings came in at $7.45 per share, well above the consensus estimate of $6.21. Revenue hit $49.83 billion, also topping the $48.69 billion analysts were looking for. The company raised its full-year adjusted earnings guidance to at least $27 per share, up from at least $26.75, and lifted its operating cash flow forecast to at least $6 billion.
So why did the stock drop 8.29% to $391.41, dragging down the entire managed-care sector?
Because investors wanted more. The guidance raise was modest relative to the size of the earnings beat. According to Reuters, Wall Street analysts noted that the raise was smaller than the magnitude of the quarterly beat, triggering a broader selloff across managed-care insurers. Shares of Molina Healthcare (MOH), Centene Corp. (CNC), Oscar Health (OSCR), and UnitedHealth Group (UNH) all traded lower.
Jefferies analyst David Windley summed it up: after the sector's rally since the first quarter, "a small beat and raise is unlikely to be satisfactory for the market."
Premium Yields and Carelon Drive Growth
Revenue increased by $400 million from a year earlier, driven by higher premium yields in the Health Benefits segment and stronger CarelonRx product revenue. Those gains were partly offset by expected declines in Medicare Advantage, Medicaid, and Employer Group risk membership.
The benefit expense ratio increased 80 basis points year over year to 89.7%, reflecting elevated medical costs in government businesses. Improved performance in the Individual Affordable Care Act business partially offset the increase. The operating expense ratio was 11.1%, while the adjusted operating expense ratio rose 100 basis points to 11%, primarily due to targeted investments in workforce and long-term capabilities.
Health Benefits operating revenue increased 3% to $42.7 billion, led by higher premium yields despite lower membership in certain government and employer plans. Medical membership totaled about 44.9 million as of June 30, down 469,000 from the prior quarter, reflecting a planned commercial fee-based customer transition and expected attrition in individual ACA and Medicaid membership.
Carelon operating revenue rose 6% to $19.2 billion, driven by the expansion of Carelon Services' risk-based solutions and higher CarelonRx product revenue.
CEO Boudreaux: Investing for 2027 Growth
Chief Executive Officer Gail Boudreaux said the company is increasing investments in key capabilities while raising its earnings outlook, adding that the moves support its goal of returning to at least 12% adjusted earnings growth in 2027. The new full-year guidance of at least $27 per share is above the Wall Street consensus of $26.91.
But for a stock that had rallied into earnings, a small step forward wasn't enough. The market wanted a leap, and Elevance delivered a shuffle. The result: a sector-wide selloff as investors recalibrated expectations.
